{
    "root": "312f4193-c4be-7ca3-e063-6394a90a36f3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250325",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        }
    ],
    "indications": "Divalproex sodium is an anti-epileptic drug indicated for: Treatment of manic episodes associated with bipolar disorder ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 )",
    "contraindications": "Divalproex sodium delayed-release tablets are intended for oral administration. Divalproex sodium delayed-release tablets should be swallowed whole and should not be crushed or chewed. \n  \n                       Patients should be informed to take divalproex sodium delayed-release tablets every day as prescribed. If a dose is missed it should be taken as soon as possible, unless it is almost time for the next dose. If a dose is skipped, the patient should not double the next dose.",
    "warningsAndPrecautions": "Divalproex sodium delayed-release tablets, USP are supplied as:\n                  \n                  The 125 mg tablets are pink colored, oval shaped, biconvex coated tablets imprinted ‘796’ with black ink on one side and plain on the other side.\n                  \n                  NDC: 70518-2665-00\n                  NDC: 70518-2665-01\n                  NDC: 70518-2665-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Recommended Storage: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Divalproex sodium should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [see Warnings and Precautions (5.1)].\n                     \n                     Divalproex sodium is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [see Warnings and Precautions (5.1)].\n                     \n                     Divalproex sodium is contraindicated in patients with known hypersensitivity to the drug\n  \n   [see Warnings and Precautions (5.12)].\n                     \n                     Divalproex sodium is contraindicated in patients with known urea cycle disorders\n  \n   [see Warnings and Precautions (5.6)].\n                     \n                     For use in prophylaxis of migraine headaches: Divalproex sodium is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception\n  \n   [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)]."
}